No anthrax vaccine testing on children -- for now
October 29, 2011 By RANDOLPH E. SCHMID , AP Science Writer in Medications
Should the anthrax vaccine be tested in children? It will be a while longer before the government decides.
An advisory board said Friday that ethical issues need to be resolved - but if that can be accomplished the vaccine can be tested in children to be sure it's safe and to learn the proper dose in case it's needed in a terrorist attack.
Because of concerns that terrorists might use the potentially deadly bacteria, the government has stockpiled the vaccine. It has been widely tested on adults but never on children.
The question is whether to do tests so doctors will know if children's immune systems respond to the shots well enough to signal protection. The children would not be exposed to anthrax.
The National Biodefense Science Board said Friday a separate review board should look into the ethical issues of doing such tests in children. If that is completed successfully, the panel, said, the Department of Health and Human Services should develop a plan for a study of the vaccine in children.
How to protect young people after an anthrax attack is a challenging issue, said Dr. Nicole Lurie, a member of the board and assistant secretary for preparedness and response at the Public Health Service. "Protecting children still stands, for me, among the most important responsibilities that we have as a nation."
The board gives advice to the Department of Health and Human Services on preparations for chemical, biological and nuclear events. Its vote was 12-1.
There is no deadline for the government to decide whether to go along. And if it does agree, it's not clear how much time it would take to find money for such research and get clearance from review boards at medical centers that would conduct studies.
Another big question is whether parents would sign up their children to test a vaccine when there is no immediate threat. It's not possible to get anthrax from the vaccine, but there are side effects. In adults, shot-site soreness, muscle aches, fatigue and headache are the main ones, and rare but serious allergic reactions have been reported.
Anthrax is among several potential bioterror weapons and is of special interest because it was used in letters sent to the media and others in 2001, claiming five lives and sickening 17. That prompted extensive screening of mail and better ventilation and testing at postal facilities and government agencies.
The FBI has blamed the attacks-by-mail on Bruce Ivins, a scientist at an Army biodefense laboratory, who committed suicide before he could be charged.
Anthrax can be difficult to treat, especially if someone has breathed anthrax spores. Millions of doses of antibiotics have been stockpiled since the 2001 episode, and two experimental toxin-clearing treatments also are being stored.
U.S. troops deploying to Iraq, Afghanistan and some other countries are required to get anthrax shots. Since 1998, more than 1 million have been vaccinated. After lawsuits objecting to the requirement, a federal judge suspended the program in 2004, finding fault in the Food and Drug Administration's process for approving the drug. The next year, the FDA reaffirmed its finding that the vaccine was safe.
©2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
Gov't considers testing anthrax vaccine in kids
Oct 28, 2011 |
not rated yet |
0
-
Alternative anthrax vaccine is tested
Aug 15, 2006 |
not rated yet |
0
-
Combination vaccine developed for smallpox and anthrax
Oct 06, 2010 |
not rated yet |
0
-
Revisiting the anthrax attacks
Jan 22, 2009 |
not rated yet |
0
-
Accused anthrax killer couldn't have done it
Oct 10, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Help at hand for people with schizophrenia
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
Alzheimer's disease, the soft target of the euthanasia debate
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
Nov 01, 2011
Rank: 1 / 5 (1)
Congratulations.